Results 11 to 20 of about 28,460 (192)

First evidence for the presence of amino acid sensing mechanisms in the fish gastrointestinal tract

open access: yesScientific Reports, 2021
This study aimed to characterize amino acid sensing systems in the gastrointestinal tract (GIT) of the carnivorous fish model species rainbow trout. We observed that the trout GIT expresses mRNAs encoding some amino acid receptors described in mammals ...
Jessica Calo   +5 more
doaj   +1 more source

Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease

open access: yesNeurobiology of Disease, 2006
We compared the neuroprotective and metabolic effects of chronic treatment with ionotropic or metabotropic glutamate receptor antagonists, in rats bearing a unilateral nigrostriatal lesion induced by 6-hydroxydopamine (6-OHDA). The ionotropic, N-methyl-d-
Marie-Thérèse Armentero   +4 more
doaj   +1 more source

Dataset of eyeblink conditioning in mice treated with the selective mGluR1 antagonist JNJ16259685

open access: yesData in Brief, 2023
Eyeblink conditioning is associated with motor learning, which requires the cerebellum and the brainstem. This article provides behavioral data on whether JNJ16259685, a selective metabotropic glutamate receptor type 1 (mGluR1) antagonist, affects ...
Shoichi Tohyama, Yasushi Kishimoto
doaj   +1 more source

Antipsychotic profiles of TASP0443294, a novel and orally active positive allosteric modulator of metabotropic glutamate 2 receptor

open access: yesJournal of Pharmacological Sciences, 2015
Glutamatergic dysfunction has been implicated in psychiatric disorders such as schizophrenia. The stimulation of metabotropic glutamate (mGlu) 2 receptor has been shown to be effective in a number of animal models of schizophrenia.
Hirohiko Hikichi   +10 more
doaj   +1 more source

Negative Modulation of the Metabotropic Glutamate Receptor Type 5 as a Potential Therapeutic Strategy in Obesity and Binge-Like Eating Behavior

open access: yesFrontiers in Neuroscience, 2021
Obesity is a multifactorial disease, which in turn contributes to the onset of comorbidities, such as diabetes and atherosclerosis. Moreover, there are only few options available for treating obesity, and most current pharmacotherapy causes severe ...
Tadeu P. D. Oliveira   +12 more
doaj   +1 more source

Optogenetics-induced activation of glutamate receptors improves memory function in mice with Alzheimer’s disease

open access: yesNeural Regeneration Research, 2019
Optogenetics is a combination of optics and genetics technology that can be used to activate or inhibit specific cells in tissues. It has been used to treat Parkinson’s disease, epilepsy and neurological diseases, but rarely Alzheimer’s disease.
Ke-Wei Wang   +4 more
doaj   +1 more source

Paeonol Protection Against Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson\'s Disease

open access: yesBasic and Clinical Neuroscience, 2021
Introduction: Parkinsonchr('39')s disease (PD) presentations comprise frequent movement disorders in the elderly with various symptoms consisting of motor and non-motor complications.
Jamileh Ghalami   +4 more
doaj  

Bioactive Benzofuran Derivatives from Cortex Mori Radicis, and Their Neuroprotective and Analgesic Activities Mediated by mGluR1

open access: yesMolecules, 2017
Four new benzofuran-type stilbene glycosides and 14 known compounds including 8 benzofuran-type stilbenes and 6 flavonoids were isolated from the traditional Chinese medicine, Cortex Mori Radicis.
Ya-Nan Wang   +13 more
doaj   +1 more source

Fragile X mental retardation protein (FMRP) and metabotropic glutamate receptor subtype 5 (mGlu5) control stress granule formation in astrocytes

open access: yesNeurobiology of Disease, 2021
Fragile X syndrome (FXS) is a common form of intellectual disability and autism caused by the lack of Fragile X Mental Retardation Protein (FMRP), an RNA-binding protein involved in RNA transport and protein synthesis.
B. Di Marco   +8 more
doaj   +1 more source

Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease

open access: yesParkinson's Disease, 2010
Clinical trials have demonstrated positive proof of efficacy of dual metabotropic glutamate receptor 2/3 (mGluR2/3) agonists in both anxiety and schizophrenia.
Hugh Chan   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy